Beovu (brolucizumab) – Risk Of Intraocular Inflammation, Retinal Vasculitis And/or Retinal Vascular Occlusion
BEOVU (brolucizumab), a medication used to treat eye conditions, is being recalled across Canada due to new safety information showing a risk of intraocular inflammation, retinal vasculitis, and retinal vascular occlusion. These conditions affect blood vessels and tissue inside the eye. The recall applies to all BEOVU products distributed in Canada.
- Product
- BEOVU (brolucizumab)
- Reason
- New safety information - Product safety
- Category
- drug recall
- Country
- Canada
- Agency
- HC-DRUGS
- Recall date
- 2022-02-03
- Status
- Ongoing
- Distribution
- Canada-wide
Official recall notice from HC-DRUGS
Recall details on Nibble Recalls: https://trynibble.app/recalls/f1713c9f-b055-48f3-933b-c439b812b813